Target intelligence / Profile preview

Immunoglobulin heavy diversity 6-25 (IGHD6-25)

Target
IGHD6-25
Molecular classification
Other (Immunoglobulin gene segment)
01

Overview

Immunoglobulin heavy diversity 6-25 (IGHD6-25) is a D (diversity) gene segment within the human immunoglobulin heavy chain locus. It does not encode a protein directly but contributes, through somatic recombination with V (variable) and J (joining) gene segments, to the generation of the variable region of immunoglobulin heavy chains during B cell development. The combinatorial usage of V, D, and J segments enables the generation of a vast array of antibodies capable of recognizing diverse antigens[1][2][3]. This gene segment is a germline DNA sequence element essential for the adaptive immune system but is not itself a receptor, enzyme, transporter, or typical drug target. IGHD6-25 is not a drug target, protein, or receptor but a genomic DNA segment involved in antibody gene assembly. There are no drugs, biomarkers, or mechanisms of drug action specific to this segment, nor are there known safety concerns related to it. The target is “incorrect” in the context of typical therapeutic target lists because it does not fulfill the role of a protein target amenable to therapeutic intervention. In summary, IGHD6-25 is a small DNA segment used in forming the variable region of immunoglobulin heavy chains and is not an individual protein, receptor, or druggable target[1][2][3].

Other names
IGHD625IGHD6-25
02

Biological functions

Generation of antibody diversityImmune response
03

Disease associations

Other (not directly implicated in diseases but involved in immune repertoire formation)

Beyond the preview

Go deeper on Immunoglobulin heavy diversity 6-25 (IGHD6-25).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoglobulin heavy diversity 6-25 (IGHD6-25).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call